Virometix closes oversubscribed financing round
Zurich - Schlieren, Switzerland (October 26, 2015)
– Virometix today announced the closing of a new financing round, which involved existing shareholders as well as a new private investor and was oversubscribed. Virometix will use the proceeds from this financing round to expand its operations and advance its vaccine candidates for infectious and viral diseases.
Virometix extends its Board of Directors and appoints a new chairman
Zurich - Schlieren, Switzerland (July 27, 2015)
– Virometix today announced the appointment of Dr. Ivan Csendes as new independent Board member and Chairman of the Board of Directors. Dr. Csendes brings in a longstanding and broad expertise from the pharmaceutical industry, including 23 years work experience at the Business Development and Licensing Departments of Ciba-Geigy and Novartis, where he was responsible for in- and out-licensing of drug candidates as well as for various drug delivery and device projects. Dr Csendes is a founding member and Board member of Swiss Healthcare Licensing Group and member of the European Pharma Licensing Group. Dr. Csendes holds a PhD in Chemistry from the University of Basel, Switzerland.
Virometix closes extension financing round
Zurich - Schlieren, Switzerland (November 19, 2014)
– Virometix today announced that it has closed an extension to its recent financing round. Virometix will use the proceeds to further speed up the development of its vaccine candidates for infectious and viral diseases.
Virometix moves to a new location
Zurich - Schlieren, Switzerland (July 21, 2014)
– Virometix today announced relocation of its operations to new premises in order to better meet the business needs of the company. The new office is located at the BIO-TECHNOPARK Zurich–Schlieren, which hosts a cluster of life science companies ranging from recent University spin-offs to leading global pharmaceutical companies.